Praxis Precision Medicines, Inc. PRAX Accrued external research and development expenses
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept prax:AccruedExternalResearchAndDevelopmentExpensesCurrent.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s accrued external research and development expenses.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s accrued external research and development expenses?
- Praxis Precision Medicines, Inc. (PRAX) reported accrued external research and development expenses of $12.94M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s accrued external research and development expenses changed year-over-year?
- Praxis Precision Medicines, Inc.'s accrued external research and development expenses increased by 11.2% year-over-year, from $11.64M to $12.94M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s accrued external research and development expenses?
- Over 5 years (2020 to 2025), Praxis Precision Medicines, Inc.'s accrued external research and development expenses has grown at a 27.7% compound annual growth rate (CAGR), from $4.21M to $14.29M.